Erudio Healtherudio.com
Clinical trial · no report yet · Early phase 1
NCT02872025
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
- NCT02872025 ↗
- Active, not recruiting
- Laura Esserman
- Focused
We haven't built an HCP commentary report on NCT02872025 (pembrolizumab and intralesional mRNA 2752 in Carcinoma, Intraductal, Noninfiltrating) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02872025 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS
- Phase
- Early phase 1
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Intraductal, Noninfiltrating
- Interventions
- Pembrolizumab; Intralesional mRNA 2752
- Arms
- CLOSED:Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase) · Experimental
- CLOSED:Pembrolizumab IL x 4 doses (Expansion Phase) · Experimental
- CLOSED:Pembrolizumab IL x 2 doses + mRNA 2752 IL x 2-4 doses (Expansion Phase) · Experimental
- mRNA-2752 Monotherapy x 2-4 doses (Escalation Cohort) · Experimental
- mRNA-2752 x 2-4 doses with or without immune checkpoint inhibitor (Expansion Cohort) · Experimental
- No active treatment · No intervention
- Enrollment
- 42
- Primary outcomes
- Maximum tolerated dose (MTD)
- Number of participants with Dose-limiting toxicities (DLTs)
- Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells
- Sponsor
- Laura Esserman with Merck Sharp & Dohme LLC, ModernaTX, Inc.
- Start
- Dec 12, 2016
- Primary completion
- Mar 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02872025 · updated Jan 30, 2025
Publications
linked from the registry- Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):288-292. doi: 10.1001/jamaoncol.2024.5927. PubMed 39821301